Detalhe da pesquisa
1.
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Ann Clin Transl Neurol;
11(5): 1338-1346, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572524
2.
Taste disorders and alopecia in myasthenia gravis.
BMC Neurol;
24(1): 139, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38664714
3.
Facioscapulohumeral muscular dystrophy Health Index: Japanese translation and validation study.
Disabil Rehabil;
: 1-10, 2024 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555736
4.
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan.
Neurol Clin Pract;
14(3): e200276, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38544885
5.
Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
EClinicalMedicine;
67: 102390, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38314057
6.
Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan.
Res Involv Engagem;
9(1): 107, 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031179
7.
Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
J Neuroimmunol;
385: 578241, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952282
8.
RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS.
Sci Adv;
9(47): eadg3193, 2023 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992159
9.
Longitudinal Changes in Neuropsychological Functioning in Japanese Patients with Myotonic Dystrophy Type 1: A Five Year Follow-Up Study.
J Neuromuscul Dis;
10(6): 1083-1092, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37599536
10.
Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan.
Orphanet J Rare Dis;
18(1): 241, 2023 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568154
11.
Optical measurement of gating pore currents in hypokalemic periodic paralysis model cells.
Dis Model Mech;
16(6)2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37139703
12.
Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan.
J Neuromuscul Dis;
10(4): 555-566, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125562
13.
The current status of medical care for myotonic dystrophy type 1 in the national registry of Japan.
Muscle Nerve;
67(5): 387-393, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762492
14.
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Neurotherapeutics;
20(2): 518-523, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36607596
15.
Hyperkalemic periodic paralysis associated with a novel missense variant located in the inner pore of Nav1.4.
Brain Dev;
45(4): 205-211, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36628799
16.
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis.
J Neurol Neurosurg Psychiatry;
94(6): 467-473, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36693723
17.
Periodic paralysis due to cumulative effects of rare variants in SCN4A with small functional alterations.
Muscle Nerve;
66(6): 757-761, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36116128
18.
Mature Myotubes Generated From Human-Induced Pluripotent Stem Cells Without Forced Gene Expression.
Front Cell Dev Biol;
10: 886879, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35706901
19.
Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1.
BMC Neurol;
22(1): 55, 2022 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164706
20.
Characteristics of myotonic dystrophy patients in the national registry of Japan.
J Neurol Sci;
432: 120080, 2022 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34923335